Joseph F Grosso
Overview
Explore the profile of Joseph F Grosso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
9268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Woo S, Turnis M, Goldberg M, Bankoti J, Selby M, Nirschl C, et al.
Cancer Res
. 2011 Dec;
72(4):917-27.
PMID: 22186141
Inhibitory receptors on immune cells are pivotal regulators of immune escape in cancer. Among these inhibitory receptors, CTLA-4 (targeted clinically by ipilimumab) serves as a dominant off-switch while other receptors...
12.
Bruno T, Rothwell C, Grosso J, Getnet D, Yen H, Durham N, et al.
Prostate
. 2011 Jul;
72(5):514-22.
PMID: 21761425
Background: The CD8 T-cell response to prostate and other cancers is often functionally diminished or absent. This may occur via deletion of tumor-specific T cells, through acquisition of an anergic...
13.
Getnet D, Grosso J, Goldberg M, Harris T, Yen H, Bruno T, et al.
Mol Immunol
. 2010 Mar;
47(7-8):1595-600.
PMID: 20226531
Relative upregulation of the Ikaros family transcription factor Helios in natural regulatory T cells (Tregs) has been reported by several groups. However, a role for Helios in regulatory T cells...
14.
Yen H, Harris T, Wada S, Grosso J, Getnet D, Goldberg M, et al.
J Immunol
. 2009 Nov;
183(11):7161-8.
PMID: 19917680
IL-17-secreting CD8 T cells (Tc17) have been described in several settings, but little is known regarding their functional characteristics. While Tc1 cells produced IFN-gamma and efficiently killed targets, Tc17 cells...
15.
Pan F, Yu H, Dang E, Barbi J, Pan X, Grosso J, et al.
Science
. 2009 Aug;
325(5944):1142-6.
PMID: 19696312
CD4+ regulatory T cells (Tregs) maintain immunological self-tolerance and immune homeostasis by suppressing aberrant or excessive immune responses. The core genetic program of Tregs and their ability to suppress pathologic...
16.
Grosso J, Goldberg M, Getnet D, Bruno T, Yen H, Pyle K, et al.
J Immunol
. 2009 May;
182(11):6659-69.
PMID: 19454660
Lymphocyte Activation Gene-3 (LAG-3) is a transmembrane protein that binds MHC class II, enhances regulatory T cell activity, and negatively regulates cellular proliferation, activation, and homeostasis of T cells. Programmed...
17.
Wada S, Yoshimura K, Hipkiss E, Harris T, Yen H, Goldberg M, et al.
Cancer Res
. 2009 May;
69(10):4309-18.
PMID: 19435909
To study the immune response to prostate cancer, we developed an autochthonous animal model based on the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse in which spontaneously developing tumors...
18.
Getnet D, Maris C, Hipkiss E, Grosso J, Harris T, Yen H, et al.
J Immunol
. 2009 Apr;
182(8):4675-85.
PMID: 19342643
Tumors express a wide variety of both mutated and nonmutated Ags. Whether these tumor Ags are broadly recognized as self or foreign by the immune system is currently unclear. Using...
19.
Harris T, Hipkiss E, Borzillary S, Wada S, Grosso J, Yen H, et al.
Prostate
. 2008 Jun;
68(12):1319-29.
PMID: 18561247
Background: Cancer immunotherapy refers to an array of strategies intended to treat progressive tumors by augmenting a patient's anti-tumor immune response. As immunotherapy is eventually incorporated into oncology treatment paradigms,...
20.
Grosso J, Drake C
Surg Oncol Clin N Am
. 2007 Nov;
16(4):861-71, x.
PMID: 18022549
For men who have hormone-refractory prostate cancer, current treatment options are somewhat limited, with docetaxel the only agent showing a significant prolongation of survival. Several groups have investigated therapeutic approaches...